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subjects with NVAF in 2011) causes a po-
tential expenditure of € 1,629,000,000 (about 
2% of total public health expenditure). This 
expenditure is mainly due to the number of 
events caused by AF (stroke, intracranial 
and extracranial hemorrhages, transient isch-
emic attacks, myocardial infarction, etc.). Of 
these, the stroke is the most important event 
in terms of economic impact for the National 
Health Service (NHS), being the third lead-
ing cause of death (after cardiovascular dis-
eases and cancer) and the leading cause of 
long-term serious disability [4].
INTRODUCTION
Atrial fibrillation (AF) is the most common 
form of alteration in cardiac rhythm, with a 
prevalence of 1-2% in the general popula-
tion [1]. AF, even in its non-valvular form 
(NVAF), is associated with more severe epi-
sodes of stroke, with a higher degree of re-
sidual disability, or associated with increased 
mortality, particularly in patients aged ≥ 75 
years [2]. In Western countries, the annual 
cost of treatment for patient with AF is es-
timated to be about € 3,000 [3], which pro-
jected on the Italian population (543,000 
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ABSTRACT
Background: atrial fibrillation (AF) is the most common form of alteration in cardiac rhythm and associated with more 
severe episodes of stroke. Treatment with oral anticoagulants vitamin K antagonists (VKA) such as warfarin, is nowadays 
the therapy of choice for stroke prevention in patients with AF, but dabigatran etexilate (DE) 150 mg twice daily was more 
clinically effective than warfarin in reducing the risk of stroke or systemic embolism, ischaemic stroke and vascular mortal-
ity whereas DE 110 mg twice daily was non-inferior to warfarin.
Aim: to assess the affordability of the use of DE for the Italian NHS, in patients with non-valvular AF (NVAF) through a 
budget impact analysis (BIA).
Methods: the BIA in a timeframe of 5 years was divided into 3 scenarios (1: current management of patients with NVAF; 
2: all patients with NVAF treated with VKA; 3: all patients with NVAF treated with DE). The population considered is 
the one with indication for anticoagulation. Analysis is from the NHS perspective: therefore, indirect costs are excluded.
Results: the underuse of oral anticoagulation, associated with the difficulty in keeping the patients treated with VKA within 
an acceptable therapeutic range, results in an enormous social and human cost, represented by a total of more than 63,000 
strokes cumulated in the 5-year period considered. The cumulative cost for the scenario 1 over the 5-year period is over € 
2.3 billion. In the scenario 2 the number of strokes avoided per year increases by -5,219 compared to no treatment (-2,368 
compared to scenario 1), although the number of events remains high (about 10,000 events/year). In the 5-year observation 
period the scenario 2 would result in a reduction in the total number of strokes (-12,323 events vs. scenario 1), and savings 
for the NHS of around 95 million Euros compared to scenario 1. In the Scenario 3 there is a reduction of more than 38,600 
of the total cumulative number of strokes vs. the scenario 1 and over 26,200 vs. scenario 2, and savings for the NHS at the 
fifth year of observation of circa 174 million Euros vs. scenario 1 and 123 million Euros vs. scenario 2.
Conclusion: DE in Italy is economically sustainable, as it allows savings for the NHS in the management of patients with 
NVAF from the second year vs. no treatment and vs. treatment with VKA.
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In Italy there are about 200,000 people af-
fected by stroke every year: of these, 40,000 
die shortly after and another 40,000 lose 
completely their self-sufficiency, completely 
changing their lives and those of their fami-
lies [4]. It is estimated that 15% of total stroke 
is attributable to subjects with AF (about 
30,000 strokes) [4]. Given these events, the 
cost to the NHS per stroke is about € 17,500, 
the annual total cost € 3,500,000,000 for all 
strokes and € 525,000,000 for those caused 
by AF [4]. Treatment with oral anticoagu-
lants vitamin K antagonists (VKA) such as 
warfarin, is nowadays the therapy of choice 
for stroke prevention in patients with atrial 
fibrillation [5]. However, the difficulty in 
maintaining the anticoagulant effect in the 
therapeutic range greatly limits its effective-
ness, increasing the probability of bleeding, 
as well as representing a contraindication to 
the prescription of therapy in patients with 
poor compliance or unable to perform the 
necessary laboratory checks. In addition, 
many patients who are administered this 
therapy, if not followed in specialized centers 
(TAO – anticoagulation therapy center) may 
suffer from inadequate anticoagulation [6]. In 
the RE-LY study (Randomized Evaluation of 
Long-Term Anticoagulation Therapy), dabi-
gatran etexilate has proved effective as war-
farin at the lowest dose (110 mg twice daily) 
and significantly more effective than warfa-
rin at the highest dose (150 mg twice daily) 
in preventing stroke and systemic embolisms 
over a two-year period of treatment in patients 
with atrial fibrillation and risk of stroke [7].
AIM OF THE STUDY
The study aims to assess the affordability of 
the use of dabigatran etexilate (DE) for the 
Italian NHS, in patients with NVAF through 
a budget impact analysis in a timeframe of 5 
years.
METHODS
Scenarios and reference population
The budget impact analysis in a timeframe of 
5 years was divided into 3 scenarios:
 - Scenario 1: current management of pa-
tients with NVAF.
 - Scenario 2: all patients with NVAF treat-
ed with VKA.
 - Scenario 3: all patients with NVAF treat-
ed with DE.
The population considered is the one with 
indication for anticoagulation. Therefore, 
also patients intolerant of VKA and patients 
with severe renal impairment are included. 
Both types of patients are distributed evenly 
(VKA-treated patients and patients treated 
with dabigatran etexilate) among the vari-
ous scenarios, avoiding biases regarding the 
comparison among the budget impacts.
Assumptions of the analysis
This was an analysis from the Italian NHS 
perspective: therefore, indirect costs are ex-
cluded, although they represent a major eco-
nomic burden, in the case of warfarin use, 
both for families and society. Moreover, for 
estimating the target population of the analy-
sis and the associated costs, the following as-
sumptions are considered:
 - In Italy, NVAF patients with indication 
for anticoagulation therapy are 335,000 
(Appendix A).
 - The risk of stroke is 4.5% per year in pa-
tients with untreated NVAF [8].
 - The reduction in the risk of ischemic 
stroke associated with the treatment with 
warfarin, at adjusted dosage in order to 
achieve INR values between 2 and 3, is 
65% [9].
 - The incidence of hemorrhagic stroke with 
warfarin, well controlled, is equal to 0.38 
x 100 patients/year [7,10].
 - The average time in therapeutic range 
(TTR) in Italy for patients treated with 
VKA is equal to 56.3% [11].
 - The odds of ischemic events is 43% in 
patients treated with warfarin with TTR 
< 60% [12].
 - The average cost of management of acute 
stroke is equal to 17,500 €/year [4].
 - The average cost of managing post-stroke 
period is equal to 7,600 €/year [13].
 - The costs of management of stroke here 
considered may be conservative, since it 
is known that the atrial fibrillation-related 
strokes are generally more severe and dis-
abling [4].
 - The average cost of INR is equal to 355 
€/year (LR Veneto data [14] updated to 
2010, Istat index).
 - The cost of warfarin is 0.05 €/day (16.2 
€/year).
 - The assumed cost of dabigatran etexilate 
is 2.10 €/day (current price in Spain; to-
day, May 2012, the lowest price in Eu-
rope).
 - Patients treated with dabigatran etexilate 
undergo creatinine clearance tests (kid-
ney check-up). We assume once a year 
(cost = 1.80 €/service according to Re-
gional Tariff).
 - There is an increase in the number of 
patients with NVAF in the considered 
years of 2% per year [15], even af-
ter considering a 12% mortality of the 
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population (about twice the mortality of 
the general population in age-matched 
groups, as indicated in the 2010 ESC 
guidelines [16]).
 - Dabigatran etexilate 150 mg causes a 
75% reduction in stroke risk compared 
with no treatment (RR = 0.25; 95%CI: 
0.12-0.51) [17].
 - Dabigatran etexilate 110 mg results in a 
65% reduction in stroke risk compared 
with no treatment (RR = 0.35; 95%CI: 
0.17-0.71) [17].
 - The incidence of hemorrhagic stroke 
with dabigatran etexilate is 0.11 x 100 
patients/year in the RE-LY study [7,10]. 
In Europe, regulatory authorities recom-
mend the use of dabigatran etexilate 150 
mg twice daily for patients younger than 
80 years (approximately 55,8% of the to-
tal population eligible to treatment) and 
110 mg twice daily for patients aged ≥80 
years (approximately 55,8% of the total 
population eligible to treatment).
In order to simplify the comparison, it was 
assumed that:
 - In every scenario, all patients are treated 
from the first day of every year, to assess 
the maximum potential impact of the var-
ious costs.
 - The adherence to the treatment for dabiga-
tran etexilate and warfarin is 95% (728 €/
year and 16,2 €/year, respectively) [7,10].
 - The datum on the time in therapeutic 
range (2 ≤ INR ≥ 3) used is that for the 
patients treated for more than 1 year. 
This is justified by the fact that interna-
tional and national studies show that, for 
patients treated for less than 1 year, the 
TTR is significantly lower than the TTR 
correlated with a longer duration of an-
ticoagulant treatment, remaining below 
the average figure of 50% [4,11]. In fact, 
as widely recognized by the international 
scientific community [3], these patients 
are at significantly greater risk of devel-
oping a stroke than others. On the other 
hand, the inclusion of this parameter in 
scenarios 1 and 2 would have lead to a 
considerable increase in the hypotheti-
cal cost of disease management or an ad-
vantage in the scenario where dabigatran 
etexilate is used. It was therefore decided 
to prefer the simplicity of analysis of the 
model and not to include this additional 
parameter.
Sensitivity analysis
Finally, a one-way sensitivity analysis was 
performed on the costs of monitoring pa-
tients on VKA therapy and on the costs of 
the drug; both parameters, taken into ac-
count, are those most affected by a high 
variability (heterogeneity of monitoring 
costs), uncertainty (the price of the drug will 
be determined by AIFA) and impact on the 
final budget impact result. The minimum 
(€ 212) and maximum (€ 446) value of the 
costs of treatment monitoring of patients on 
VKA therapy was extracted from a research 
done by ANMDO (2012) in collaboration 
with the Centro Interdipartimentale di Studi 
Internazionali sull’Economia e lo Sviluppo 
(CEIS) at the Faculty of Economics, Univer-
sity of Rome Tor Vergata, and the Centro di 
Ricerche e Studi in Management Sanitario 
(CERISMAS) at the Catholic University of 
Sacro Cuore in Rome. Variations of +/-10% 
were applied to the cost of the drug.
RESULTS
Scenario 1: current management 
of patients with NVAF
In the year 1 (2011), 335,000 individuals 
with NVAF have indication for oral antico-
agulation, of whom approximately 183,000 
are treated with VKA, while the remaining 
152,000 aren’t treated with oral anticoagu-
lants. In Table I the current situation versus 
no treatment is analyzed in terms of events 
prevented by the current management of dis-
ease (year 1). Table II shows the 5-year pre-
diction of ischemic and hemorrhagic strokes 
in the Italian situation.
From Table I it is clear how the current treat-
ment of NVAF involves the reduction of 
only 2,851 strokes, in the first year of ob-
servation, compared with the total number 
of strokes developed in the scenario of total 
non-treatment (15,075). This confirms that, 
despite the enormous organizational effort, 
there is still a major unmet need in the man-
agement of NVAF. The underuse of oral an-
ticoagulation, associated with the difficulty 
in keeping the patients treated with VKA 
within an acceptable therapeutic range, re-
sults in an enormous social and human cost, 
represented by a total of more than 63,000 
strokes cumulated in the 5-year period con-
sidered (Table II). 
Starting from the cost assumptions reported 
in the background when presenting the sce-
narios, Table III shows the current cost of 
management of NVAF. Table III shows that 
the cumulative cost over the 5-year period is 
over € 2.3 billions and the major cost genera-
tor in the management of NVAF is the cost of 
stroke management (€ 2.03 billions). Indi-
rect costs, burdening families and society, 
were not considered in this analysis. Accord-
ing to the CENSIS survey, presented in 2011 
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at the World Day of stroke, every stroke pa-
tient costs about € 30,000 to the family per 
year [18].
No treatment
Total patients with NVAF (nr.) 335,000 
Risk of stroke (%/year) 4.50
Total strokes (nr./year) 15,075 
Current situation
 Pts treated with VKA Pts not treated with VKA
Total patients with NVAF (nr.) 183,000 152,000 
Number of strokes (nr./year) 8,235 6,840 
VKA: risk reduction with “real life”-TTR of 56.3% (%) -43 0
Ischemic strokes (nr./year) 4,694 6,840 
Total ischemic strokes (nr./year) 11,534 
Hemorrhagic strokes (nr./year) 690 0*
Total hemorrhagic strokes (nr./year) 690 
Total ischemic/hemorrhagic strokes (nr./year) 12,224 
Total ischemic/hemorrhagic strokes prevented vs. no treatment (nr./year) 2,851 
Table I. Current situation vs. no treatment (year 1)
* The figure of hemorrhagic strokes (total per year), in the group of patients not treated with VKA, has been considered to be zero to simplify the calculation
Year 1 Year 2 Year 3 Year 4 Year 5 Total
Events in no treatment (nr.) 15,075 15,377 15,684 15,998 16,318 78,452
Events in current situation (nr.) 12,224 12,468 12,718 12,972 13,232 63,614
Prevented events current situation vs. no treatment (nr.) 2,851 2,909 2,966 3,026 3,086 14,838
Table II. Prevented events (ischemic and hemorrhagic strokes), current situation vs. no treatment over 5 year
Cost item Year 1 Year 2 Year 3 Year 4 Year 5 Total
INR monitoring (€ x 1,000) 64,965 6,264 67,590 68,941 70,320 338,080
VKA (€ x 1,000) 2,965 3,024 3,084 3,146 3,209 15,428
Management of ischemic/hemorrhagic stroke (€ x 1,000) 213,920 311,228 406,259 503,086 601,745 2,036,237
Total cost (€ x 1,000) 281,850 380,516 476,933 575,173 675,274 2,389,745
Table III. Current cost of management of NVAF in the scenario 1 (current situation)
Scenario 2: all patients with 
NVAF treated with VKA
Scenario 2 was developed on the assump-
tion that all patients with NVAF are treated 
with VKA. This is a hypothetical scenario, 
since there are both structural and therapeutic 
limitations. Structural limitations due to the 
uneven presence of anticoagulation therapy 
centers on the Italian territory, despite such 
therapy is available for over 50 years. Thera-
peutic limitations due to:
 - Resistance to the use of VKA for fear of 
bleeding.
 - Difficult management of this therapy, 
making more than 30% of patients treated 
with VKA discontinue therapy after one 
year.
 - Difficulty in maintaining the patients 
treated with VKA within an acceptable 
TTR.
Table IV lists the number of ischemic and 
hemorrhagic strokes resulting from this sce-
nario, and how many of them would be 
avoided in comparison with the current situa-
tion. Table V shows the prediction of the 
5-year period of ischemic and hemorrhagic 
strokes after treatment with VKA of the en-
tire Italian population with NVAF.
In this scenario (Table IV), the number of 
strokes avoided per year increases to -5,219 
compared to no treatment (-2,368 compared 
to the current situation), although the number 
of events remains high (about 10,000 events/
year; Table V). Starting from the cost as-
sumptions reported in methods section, Table 
VI shows the cost of management of NVAF if 
all patients were treated with VKA. Again, as 
in the previous scenario, the cumulative cost 
over the 5-year period is over 2 billion Euros 
(2.294 billion Euros).
Although in the presence of a theoretical ex-
tensive use of the VKA on all patients, the 
difficulty of maintaining within an acceptable 
therapeutic range the patients treated with 
VKA imposes an enormous social and human 
cost, represented by a total of approximately 
No treatment
Total patients with NVAF (nr.) 335,000 
Risk of stroke (%/year) 4.50
Total strokes (nr./year) 15,075 
Pts treated with VKA
Total patients with NVAF (nr.) 335,000
VKA: risk reduction with “real life”-TTR of 56.3% -43%
Total observed ischemic strokes (nr./year) 8,593 
Total hemorrhagic strokes (nr./year)* 1,263
Total ischemic/hemorrhagic strokes (nr./year) 9,856 
Total ischemic/hemorrhagic strokes prevented vs. no treatment 
(nr./year)
5,219
Table IV. Patients treated with VKA vs. no treatment (year 1)
* 0.38% per year
 Year 1 Year 2 Year 3 Year 4 Year 5 Total
Events in no treatment (nr.) 15,075 15,377 15,684 15,998 16,318 78,452
Events in VKA treatment (nr.) 9,856 10,053 10,254 10,459 10,668 51,290
Prevented events VKA vs. no treatment (nr.) 5,219 5,323 5,430 5,539 5,649 27,160
Table V. Prevented events (ischemic and hemorrhagic strokes) VKA treatment vs. no treatment over 5 year
Cost item Year 1 Year 2 Year 3 Year 4 Year 5 Total
INR monitoring (€ x 1,000) 118,925 121,304 123,730 126,204 128,728  618,890
VKA (€ x 1,000) 5,427 5,536 5,646 5,759 5,874  28,242
Management of ischemic/hemorrhagic stroke (€ x 1,000) 172,479 250,928 329,447 408,035 486,696 1,647,585
Total cost (€ x 1,000) 296,831 377,767 458,823 539,999 621,298 2,294,718
Table VI. Cost of patients treated with VKA vs. no treatment over 5 years
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Table IV lists the number of ischemic and 
hemorrhagic strokes resulting from this sce-
nario, and how many of them would be 
avoided in comparison with the current situa-
tion. Table V shows the prediction of the 
5-year period of ischemic and hemorrhagic 
strokes after treatment with VKA of the en-
tire Italian population with NVAF.
In this scenario (Table IV), the number of 
strokes avoided per year increases to -5,219 
compared to no treatment (-2,368 compared 
to the current situation), although the number 
of events remains high (about 10,000 events/
year; Table V). Starting from the cost as-
sumptions reported in methods section, Table 
VI shows the cost of management of NVAF if 
all patients were treated with VKA. Again, as 
in the previous scenario, the cumulative cost 
over the 5-year period is over 2 billion Euros 
(2.294 billion Euros).
Although in the presence of a theoretical ex-
tensive use of the VKA on all patients, the 
difficulty of maintaining within an acceptable 
therapeutic range the patients treated with 
VKA imposes an enormous social and human 
cost, represented by a total of approximately 
No treatment
Total patients with NVAF (nr.) 335,000 
Risk of stroke (%/year) 4.50
Total strokes (nr./year) 15,075 
Pts treated with VKA
Total patients with NVAF (nr.) 335,000
VKA: risk reduction with “real life”-TTR of 56.3% -43%
Total observed ischemic strokes (nr./year) 8,593 
Total hemorrhagic strokes (nr./year)* 1,263
Total ischemic/hemorrhagic strokes (nr./year) 9,856 
Total ischemic/hemorrhagic strokes prevented vs. no treatment 
(nr./year)
5,219
Table IV. Patients treated with VKA vs. no treatment (year 1)
* 0.38% per year
 Year 1 Year 2 Year 3 Year 4 Year 5 Total
Events in no treatment (nr.) 15,075 15,377 15,684 15,998 16,318 78,452
Events in VKA treatment (nr.) 9,856 10,053 10,254 10,459 10,668 51,290
Prevented events VKA vs. no treatment (nr.) 5,219 5,323 5,430 5,539 5,649 27,160
Table V. Prevented events (ischemic and hemorrhagic strokes) VKA treatment vs. no treatment over 5 year
Cost item Year 1 Year 2 Year 3 Year 4 Year 5 Total
INR monitoring (€ x 1,000) 118,925 121,304 123,730 126,204 128,728  618,890
VKA (€ x 1,000) 5,427 5,536 5,646 5,759 5,874  28,242
Management of ischemic/hemorrhagic stroke (€ x 1,000) 172,479 250,928 329,447 408,035 486,696 1,647,585
Total cost (€ x 1,000) 296,831 377,767 458,823 539,999 621,298 2,294,718
Table VI. Cost of patients treated with VKA vs. no treatment over 5 years
51,000 strokes cumulated in the 5-year peri-
od under analysis.
The Table VII shows that an extensive use of 
VKA, scenario 2, in the 5-year observation 
period would result in:
 - A reduction in the total number of strokes 
(12,323 fewer events in scenario 2 than in 
scenario 1).
 - Savings for the NHS of around 95 million 
Euros compared to scenario 1.
Scenario 3: all patients with NVAF 
treated with dabigatran etexilate
Scenario 3: all patients with NVAF treated 
with dabigatran etexilate Tables VIII-IX 
show the potential ischemic and hemorrhagic 
strokes when using dabigatran etexilate on 
the entire population with NVAF.
Tables VIII and IX show that:
 - The total number of strokes per year is 
significantly reduced compared with no 
treatment (about 4,800 strokes compared 
with about 15,075 of no treatment);
 - The number of strokes avoided per year is 
about 7,500 compared to scenario 1 and 
about 5,000 compared to scenario 2.
Scenario 2 vs. scenario 1 Year 1 Year 2 Year 3 Year 4 Year 5 Total
Ischemic strokes (nr.) -2,941 -3,000 -3,060 -3,121 -3,184 -15,306
Hemorrhagic strokes (nr.) 573 585 596 608 620 2,983
Total ischemic/hemorrhagic strokes (nr.) -2,368 -2,415 -2,464 -2,513 -2,563 -12,323
Cost of INR monitoring (€ x 1,000)  53,960  55,039  56,140  57,263  58,408 280,810
Drug cost (€ x 1,000) 2,462 2,512  2,562 2,613 2,665 12,814
Cost of management of ischemic/hemorrhagic stroke 
(€ x 1,000)
-41,441 -60,299 -76,812 -95,051 -115,049 -388,651
Total cost (€ x 1,000) 14,982 -2,748 -18,110 -35,175 -53,975 -95,027
Table VII. VKA treatment of all patients vs. current situation over 5 years
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Similarly to the previous scenarios, starting 
from the cost assumptions reported in the 
background, and using a daily cost of dabiga-
tran etexilate equal to € 2.10 (the lowest in Eu-
rope in May 2012: current price in Spain), Ta-
ble X reports the management costs of NVAF.
Figures 1, 2 and 3 show the comparison 
among the scenario 3 (all the patients treated 
with dabigatran etexilate) and other scenarios 
in terms of events and costs.  
An extensive use of dabigatran etexilate 
would cause:
 - A reduction of more than 38,500 of the 
total cumulative number of strokes vs. the 
current scenario and over 26,297 vs. the 
No treatment
Total patients with NVAF (nr.) 335,000 
Risk of stroke (%/year) 4.50
Total strokes (nr./year) 15,075 
Pts treated with DE
 DE 150 mg (pts < 80 years) DE 110 mg (pts ≥ 80 years)
Patients with NVAF (nr.) 187,000 148,000 
DE: reduction in the risk of stroke (%) -75 -65
Ischemic strokes (nr./year) 2,059 2,394 
Total ischemic strokes (nr./year) 4,435
Hemorrhagic strokes (nr./year) 205 163 
Total hemorrhagic strokes (nr./year) 368 
Total ischemic/hemorrhagic strokes (nr./year) 4,803 
Total ischemic/hemorrhagic strokes prevented vs. no treatment 
(nr./year)
10,272
Table VIII. Patients treated with dabigatran etexilate (DE) vs. no treatment (year 1)
 Year 1 Year 2 Year 3 Year 4 Year 5 Total
Events in no treatment (nr.) 15,075 15,377 15,684 15,998 16,318 78,452
Events in DE treatment (nr.) 4,803 4,899 4,997 5,097 5,199 24,995
Prevented events DE vs. no treatment (nr.) 10,272 10,478 10,687 10,901 11,119 53,457
Table IX. Prevented events (ischemic and hemorrhagic strokes): treatment with dabigatran etexilate (DE) over 5 years
Cost item Year 1 Year 2 Year 3 Year 4 Year 5 Total
DE* (€ x 1,000) 244,542 249,432 254,421 259,510 264,700 1,272,604
Management cost of ischemic + hemorrhagic stroke (€ x 1,000) 84,047 122,153 160,289 198,458 236,658 801,605
Total cost (€ x 1,000) 328,589 371,585 414,710 457,967 501,358 2,074,209
Table X. Cost of patients treated with dabigatran etexilate (DE)
* Cost/day = € 2.10; Compliance rate 95%
Figure 1.Number of events (hemorrhagic and ischemic strokes) in the various scenarios
DE = dabigatran etexilate
Figure 2.Differences in cost of dabigatran etexilate vs. current scenario
Figure 3. Differences in cost of dabigatran etexilate vs. treatment with VKA
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Similarly to the previous scenarios, starting 
from the cost assumptions reported in the 
background, and using a daily cost of dabiga-
tran etexilate equal to € 2.10 (the lowest in Eu-
rope in May 2012: current price in Spain), Ta-
ble X reports the management costs of NVAF.
Figures 1, 2 and 3 show the comparison 
among the scenario 3 (all the patients treated 
with dabigatran etexilate) and other scenarios 
in terms of events and costs.  
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Total hemorrhagic strokes (nr./year) 368 
Total ischemic/hemorrhagic strokes (nr./year) 4,803 
Total ischemic/hemorrhagic strokes prevented vs. no treatment 
(nr./year)
10,272
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DE* (€ x 1,000) 244,542 249,432 254,421 259,510 264,700 1,272,604
Management cost of ischemic + hemorrhagic stroke (€ x 1,000) 84,047 122,153 160,289 198,458 236,658 801,605
Total cost (€ x 1,000) 328,589 371,585 414,710 457,967 501,358 2,074,209
Table X. Cost of patients treated with dabigatran etexilate (DE)
* Cost/day = € 2.10; Compliance rate 95%
Figure 1.Number of events (hemorrhagic and ischemic strokes) in the various scenarios
DE = dabigatran etexilate
Figure 2.Differences in cost of dabigatran etexilate vs. current scenario
Figure 3. Differences in cost of dabigatran etexilate vs. treatment with VKA
treatment with VKA, with all the obvi-
ous social and health benefits in terms of 
health “saved”.
 - An increase in the cost of drug treatment, 
which in this case must be considered as 
the potential maximal expenditure.
 - Savings for the NHS at the fifth year of 
observation of 173 million Euros vs. the 
current treatment and 123 million Euros 
vs. treatment with VKA.
The savings from the reduction of indirect 
costs of both society and families of patients 
with NVAF should be added to all this, result-
ing in huge direct and indirect savings for the 
society.
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SENSITIVITY ANALYSIS
Cost of monitoring of the patient 
receiving VKA therapy = € 212
As showed in Table XI an extensive use of 
dabigatran etexilate would result in:
 - Also in this situation, a saving for the 
NHS at the fifth year of observation of 71 
million Euros vs. the treatment with VKA 
(-43% compared to the basal hypothesis).
 - A reduction of 26,297 in the total number 
of cumulative strokes vs. the treatment 
with VKA, with all the obvious social and 
health benefits in terms of health “saved” 
(savings in terms of clinical benefit re-
main unchanged).
Cost of monitoring of the patient 
receiving VKA therapy € 446
As showed in Table XII, an extensive use of 
dabigatran etexilate would result in:
 - A saving for the NHS at the fifth year of 
observation of 156 million Euros vs. the 
treatment with VKA (+27% compared to 
the basal hypothesis).
 - A reduction of 26,297 in the total number 
of cumulative strokes vs. the treatment 
with VKA, with all the obvious social and 
health benefits in terms of health “saved” 
(savings in terms of clinical benefit re-
main unchanged).
Cost of dabigatran etexilate 1.89 €/
day (-10% vs. basal hypothesis)
As showed in Table XIII an extensive use of 
dabigatran etexilate would result in:
 - In this situation a saving for the NHS at the 
fifth year of observation of 149 million Eu-
ros vs. the treatment with VKA (+24,6% 
compared to the basal hypothesis).
 - A reduction of 26,297 in the total number 
of cumulative strokes vs. the treatment 
with VKA, with all the obvious social and 
health benefits in terms of health “saved” 
(savings in terms of clinical benefit re-
main unchanged).
Cost of dabigatran etexilate 2.31 €/
day (+10% vs. basal hypothesis)
As showed in Table XIV an extensive use of 
dabigatran etexilate would result in :
 - Also in this situation a saving for the 
NHS at the fifth year of observation of 96 
million Euros vs. the treatment with VKA 
(-21% compared to the basal hypothesis).
 - A reduction of 26,297 in the total number 
of cumulative strokes vs. the treatment 
with VKA, with all the obvious social and 
health benefits in terms of health “saved” 
(savings in terms of clinical benefit re-
main unchanged).
Scenario 3 vs. scenario 2 Year 1 Year 2 Year 3 Year 4 Year 5 Total
Ischemic strokes (nr.) -4,158 -4,241 -4,326 -4,413 -4,501 -21,638
Hemorrhagic strokes (nr.) -895 -913 -931 -950 -969 -4,659
Total ischemic/hemorrhagic strokes (nr.) -5,053 -5,154 -5,257 -5,363 -5,470 -26,297
Cost of INR monitoring (€ x 1,000) -71,020 -72,440 -73,889 -75,367 -76,874 -369,591
Drug cost (€ x 1,000) 236,150 240,873 245,690 250,604 255,616 1,228,934
Cost of management of ischemic/hemorrhagic stroke 
(€ x 1,000)
-88,432 -128,776 -169,157 -209,578 -250,038 -845,980
Total cost (€ x 1,000) 76,698 39,657 2,644 -34,341 -71,296 13,363
Table XI. Dabigatran etexilate vs. treatment with VKA (cost of monitoring = € 212)
Scenario 3 vs. scenario 2 Year 1 Year 2 Year 3 Year 4 Year 5 Total
Ischemic strokes (nr.) -4,158 -4,241 -4,326 -4,413 -4,501 -21,638
Hemorrhagic strokes (nr.) -895 -913 -931 -950 -969 -4,659
Total ischemic/hemorrhagic strokes (nr.) -5,053 -5,154 -5,257 -5,363 -5,470 -26,297
Cost of INR monitoring (€ x 1,000) -149,410 -152,398 -155,446 -158,555 -161,726 -777,536
Drug cost (€ x 1,000) 236,150 240,873 245,690 250,604 255,616 1,228,934
Cost of management of ischemic/hemorrhagic stroke 
(€ x 1,000)
-88,432 -128,776 -169,157 -209,578 -250,038 -845,980
Total cost (€ x 1,000) -1,692 -40,301 -78,913 -117,529 -156,148 -394,582
Table XII. Dabigatran etexilate vs. VKA treatment (cost of monitoring = € 446)
Scenario 3 vs. scenario 2 Year 1 Year 2 Year 3 Year 4 Year 5 Total 
Ischemic strokes (nr.) -4,158 -4,241 -4,326 -4,413 -4,501 -21,638
Hemorrhagic strokes (nr.) -895 -913 -931 -950 -969 -4,659
Total ischemic/hemorrhagic strokes (nr.) -5,053 -5,154 -5,257 -5,363 -5,470 -26,297
Cost of INR monitoring (€ x 1,000) -118,925 -121,304 -123,730 -126,204 -128,728 -618,890
Drug cost (€ x 1,000) 211,756 215,991 220,311 224,717 229,212 1,101,988
Cost of management of ischemic/hemorrhagic stroke 
(€ x 1,000)
-88,432 -128,776 -169,157 -209,578 -250,038 -845,980
Total cost (€ x 1,000) 4,399 -34,088 -72,576 -111,065 -149,554 -362,883
Table XIII. Dabigatran etexilate (1,89 €/die) vs. VKA treatment
Scenario 3 vs. scenario 2 Year 1 Year 2 Year 3 Year 4 Year 5 Total
Ischemic strokes (nr.) -4,158 -4,241 -4,326 -4.413 -4,501 -21,638
Hemorrhagic strokes (nr.) -895 -913 -931 -950 -969 -4,659
Total ischemic/hemorrhagic strokes (nr.) -5,053 -5,154 -5,257 -5,363 -5,470 -26,297
Cost of INR monitoring (€ x 1,000) -118,925 -121,304 -123,730 -126,204 -128,728 -618,890
Drug cost (€ x 1,000) 260,544 265,755 271,070 276,491 282,021 1,355,881
Cost of management of ischemic/hemorrhagic stroke 
(€ x 1,000)
-88,432 -128,776 -169,157 -209,578 -250,038 -845,980
Total cost (€ x 1,000) 53,187 15,676 -21,817 -59,291 -96,745 -108,990
Table XIV. Dabigatran etexilate vs. VKA treatment
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SENSITIVITY ANALYSIS
Cost of monitoring of the patient 
receiving VKA therapy = € 212
As showed in Table XI an extensive use of 
dabigatran etexilate would result in:
 - Also in this situation, a saving for the 
NHS at the fifth year of observation of 71 
million Euros vs. the treatment with VKA 
(-43% compared to the basal hypothesis).
 - A reduction of 26,297 in the total number 
of cumulative strokes vs. the treatment 
with VKA, with all the obvious social and 
health benefits in terms of health “saved” 
(savings in terms of clinical benefit re-
main unchanged).
Cost of monitoring of the patient 
receiving VKA therapy € 446
As showed in Table XII, an extensive use of 
dabigatran etexilate would result in:
 - A saving for the NHS at the fifth year of 
observation of 156 million Euros vs. the 
treatment with VKA (+27% compared to 
the basal hypothesis).
 - A reduction of 26,297 in the total number 
of cumulative strokes vs. the treatment 
with VKA, with all the obvious social and 
health benefits in terms of health “saved” 
(savings in terms of clinical benefit re-
main unchanged).
Cost of dabigatran etexilate 1.89 €/
day (-10% vs. basal hypothesis)
As showed in Table XIII an extensive use of 
dabigatran etexilate would result in:
 - In this situation a saving for the NHS at the 
fifth year of observation of 149 million Eu-
ros vs. the treatment with VKA (+24,6% 
compared to the basal hypothesis).
 - A reduction of 26,297 in the total number 
of cumulative strokes vs. the treatment 
with VKA, with all the obvious social and 
health benefits in terms of health “saved” 
(savings in terms of clinical benefit re-
main unchanged).
Cost of dabigatran etexilate 2.31 €/
day (+10% vs. basal hypothesis)
As showed in Table XIV an extensive use of 
dabigatran etexilate would result in :
 - Also in this situation a saving for the 
NHS at the fifth year of observation of 96 
million Euros vs. the treatment with VKA 
(-21% compared to the basal hypothesis).
 - A reduction of 26,297 in the total number 
of cumulative strokes vs. the treatment 
with VKA, with all the obvious social and 
health benefits in terms of health “saved” 
(savings in terms of clinical benefit re-
main unchanged).
Scenario 3 vs. scenario 2 Year 1 Year 2 Year 3 Year 4 Year 5 Total
Ischemic strokes (nr.) -4,158 -4,241 -4,326 -4,413 -4,501 -21,638
Hemorrhagic strokes (nr.) -895 -913 -931 -950 -969 -4,659
Total ischemic/hemorrhagic strokes (nr.) -5,053 -5,154 -5,257 -5,363 -5,470 -26,297
Cost of INR monitoring (€ x 1,000) -71,020 -72,440 -73,889 -75,367 -76,874 -369,591
Drug cost (€ x 1,000) 236,150 240,873 245,690 250,604 255,616 1,228,934
Cost of management of ischemic/hemorrhagic stroke 
(€ x 1,000)
-88,432 -128,776 -169,157 -209,578 -250,038 -845,980
Total cost (€ x 1,000) 76,698 39,657 2,644 -34,341 -71,296 13,363
Table XI. Dabigatran etexilate vs. treatment with VKA (cost of monitoring = € 212)
Scenario 3 vs. scenario 2 Year 1 Year 2 Year 3 Year 4 Year 5 Total
Ischemic strokes (nr.) -4,158 -4,241 -4,326 -4,413 -4,501 -21,638
Hemorrhagic strokes (nr.) -895 -913 -931 -950 -969 -4,659
Total ischemic/hemorrhagic strokes (nr.) -5,053 -5,154 -5,257 -5,363 -5,470 -26,297
Cost of INR monitoring (€ x 1,000) -149,410 -152,398 -155,446 -158,555 -161,726 -777,536
Drug cost (€ x 1,000) 236,150 240,873 245,690 250,604 255,616 1,228,934
Cost of management of ischemic/hemorrhagic stroke 
(€ x 1,000)
-88,432 -128,776 -169,157 -209,578 -250,038 -845,980
Total cost (€ x 1,000) -1,692 -40,301 -78,913 -117,529 -156,148 -394,582
Table XII. Dabigatran etexilate vs. VKA treatment (cost of monitoring = € 446)
Scenario 3 vs. scenario 2 Year 1 Year 2 Year 3 Year 4 Year 5 Total 
Ischemic strokes (nr.) -4,158 -4,241 -4,326 -4,413 -4,501 -21,638
Hemorrhagic strokes (nr.) -895 -913 -931 -950 -969 -4,659
Total ischemic/hemorrhagic strokes (nr.) -5,053 -5,154 -5,257 -5,363 -5,470 -26,297
Cost of INR monitoring (€ x 1,000) -118,925 -121,304 -123,730 -126,204 -128,728 -618,890
Drug cost (€ x 1,000) 211,756 215,991 220,311 224,717 229,212 1,101,988
Cost of management of ischemic/hemorrhagic stroke 
(€ x 1,000)
-88,432 -128,776 -169,157 -209,578 -250,038 -845,980
Total cost (€ x 1,000) 4,399 -34,088 -72,576 -111,065 -149,554 -362,883
Table XIII. Dabigatran etexilate (1,89 €/die) vs. VKA treatment
Scenario 3 vs. scenario 2 Year 1 Year 2 Year 3 Year 4 Year 5 Total
Ischemic strokes (nr.) -4,158 -4,241 -4,326 -4.413 -4,501 -21,638
Hemorrhagic strokes (nr.) -895 -913 -931 -950 -969 -4,659
Total ischemic/hemorrhagic strokes (nr.) -5,053 -5,154 -5,257 -5,363 -5,470 -26,297
Cost of INR monitoring (€ x 1,000) -118,925 -121,304 -123,730 -126,204 -128,728 -618,890
Drug cost (€ x 1,000) 260,544 265,755 271,070 276,491 282,021 1,355,881
Cost of management of ischemic/hemorrhagic stroke 
(€ x 1,000)
-88,432 -128,776 -169,157 -209,578 -250,038 -845,980
Total cost (€ x 1,000) 53,187 15,676 -21,817 -59,291 -96,745 -108,990
Table XIV. Dabigatran etexilate vs. VKA treatment
DISCUSSION
The current treatment of NVAF involves the 
reduction of only 2,851 strokes, in the first 
year of observation, compared with the total 
number of strokes developed in the scenario 
of total non-treatment (15,075). This con-
firms that, despite the enormous organiza-
tional effort, there is still a major unmet need 
in the management of NVAF. The underuse 
of oral anticoagulation, associated with the 
difficulty in keeping the patients treated 
with VKA within an acceptable therapeutic 
range, results in an enormous social and hu-
man cost, represented by a total of more than 
63,000 strokes cumulated in the 5-year pe-
riod considered (Table II). The cumulative 
cost for the current treatment of NVAF over 
the 5-year period exceeds € 2.3 billions and 
the major cost generator in NVAF manage-
ment is stroke management cost (2.03 bil-
lions). Indirect costs, burdening families and 
society, were not considered in this analysis. 
According to the CENSIS survey, presented 
in 2011 at the World Day of stroke, every 
stroke patient costs about € 30,000 to his/her 
family per year [18]. The number of avoided 
strokes per year, resulting from the scenario 
where all NVAF patients are treated with 
VKA, amounts to 5,219 compared to no 
treatment (-2,368 compared to the current 
situation), although the number of events re-
mains high (about 10,000 events/year; Table 
V). Again, as in the previous scenario, the 
cumulative cost over the 5-year period is 
over 2 billion Euros (2.294 billion Euros). 
Similarly to the previous scenarios, start-
ing from the cost assumptions reported in 
the background, and using a daily cost of 
dabigatran etexilate equal to 2.10 Euros (the 
lowest in Europe in May 2012: current price 
in Spain), an extensive use of dabigatran 
etexilate would cause:
 - A reduction of more than 38,500 of the 
total cumulative number of strokes vs. the 
current scenario and over 26,297 vs. the 
treatment with VKA, with all the obvi-
ous social and health benefits in terms of 
health “saved”.
 - An increase in the cost of drug treatment, 
which in this case must be considered as 
the potential maximal expenditure.
 - Savings for the NHS at the fifth year of 
observation of 173 million Euros vs. the 
current treatment and 123 million Euros 
vs. treatment with VKA.
The savings from the reduction of indirect 
costs of both society and families of patients 
with NVAF should be added to all this, result-
ing in huge direct and indirect savings for the 
society.
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Finally dabigatran etexilate allows significant 
savings in indirect costs for society and fami-
lies involved in a debilitating disease such as 
stroke. These costs are inherently difficult to 
quantify, yet priceless when considering the 
socio-emotional impact caused by a stroke, 
not only for the patient but also for all the 
relatives involved in this important event.
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CONCLUSIONS
According to the model used in the present 
study, which includes both epidemiologic 
and economic data, it is possible to affirm 
that marketing dabigatran etexilate in Italy 
with the new SPAF (stroke prevention in 
atrial fibrillation) indication is economically 
sustainable: it allows savings for the NHS in 
the management of patients with NVAF from 
the second year vs. no treatment and vs. treat-
ment with VKA. Furthermore it appears so-
cially and ethically convenient as it allows a 
significant overall increase in expectancy and 
quality of life of patients with NVAF, through 
the reduction of the total number of strokes. 
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APPENDIX A
Figure 1A shows the basis for the calculation 
of patients with non-valvular atrial fibrilla-
tion (NVAF) eligible for treatment
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Figure 1A. Bases for the calculation of patients with (NVAF) eligible for treatment
1 AF based on data from Osservatorio Epidemiologico Cardiovascolare [1] and Servizio 
Epidemiologico della Regione Veneto [2] applied to the Italian population, ISTAT 2011 [3]
2 32.2% cases of valvular AF; from ATA-AF study by ANMCO and FADOI 2011 [4]
3 22% are undiagnosed; from market research IMS 2010 [5]
4 10% with contraindication to OA; conservative estimate compared to 22% recorded in 
ATA-AF study by ANMCO and FADOI 2011 [4]
5 12% CHADS = 0; from survey SIMG 2011 [6]
